Lumacaftor-ivacaftor in the Treatment of Cystic Fibrosis: Design, Development and Place in Therapy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2019 Aug 15

PMID 31409974

Citations 20

Authors

G J Connett

Affiliations

Soon will be listed here.

Abstract

Lumacaftor-ivacaftor is a combination of two small molecule therapies targeting the basic defect in cystic fibrosis (CF) at a cellular level. It is a precision medicine and its effects are specific to individuals with two copies of the p.Phe508del gene mutation. The drug combination works by restoring functioning CF transmembrane conductance regulator (CFTR) protein in cell surface membranes and was the first CFTR modulator licensed for the homozygous p.Phe508del genotype. The drug is a combination of a CFTR corrector and potentiator. Lumacaftor, the corrector, works by increasing the trafficking of CFTR proteins to the outer cell membrane. Ivacaftor, the potentiator, works by enabling the opening of what would otherwise be a dysfunctional chloride channel. In vivo lumacaftor-ivacaftor improves Phe508del-CFTR activity in airways, sweat ducts and intestine to approximately 10-20% of normal CFTR function with greater reductions in sweat chloride levels in children versus adults. Its use results in a modest improvement in lung function and a decreased rate of subsequent decline. Perhaps more importantly, those treated report increased levels of well-being and their rate of respiratory exacerbations is significantly improved. This review traces the development and use of this combination of CFTR modulators, the first licensed drug for treating the homozygous p.Phe508del CF genotype at the intracellular level by correcting the protein defect.

Citing Articles

Modelling and targeting mechanical forces in organ fibrosis.

Mascharak S, Guo J, Griffin M, Berry C, Wan D, Longaker M Nat Rev Bioeng. 2024; 2(4):305-323.

PMID: 39552705 PMC: 11567675. DOI: 10.1038/s44222-023-00144-3.

Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor suggest benefits beyond improved CFTR channel function.

Hampton T, Barnaby R, Roche C, Nymon A, Fukutani K, MacKenzie T Am J Physiol Lung Cell Mol Physiol. 2024; 327(6):L905-L916.

PMID: 39437760 PMC: 11684945. DOI: 10.1152/ajplung.00272.2024.

Cystic Fibrosis: A Journey through Time and Hope.

Trouve P, Saint Pierre A, Ferec C Int J Mol Sci. 2024; 25(17).

PMID: 39273547 PMC: 11394767. DOI: 10.3390/ijms25179599.

Couple-close construction of polycyclic rings from diradicals.

Long A, Oswood C, Kelly C, Bryan M, MacMillan D Nature. 2024; 628(8007):326-332.

PMID: 38480891 PMC: 11487475. DOI: 10.1038/s41586-024-07181-x.

An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents.

Anton-Paduraru D, Murgu A, Donos M, Trofin F, Azoicai A, Popovici P Children (Basel). 2023; 10(12).

PMID: 38136081 PMC: 10741586. DOI: 10.3390/children10121879.

References

Pedemonte N, Lukacs G, Du K, Caci E, Zegarra-Moran O, Galietta L . Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005; 115(9):2564-71. PMC: 1190372. DOI: 10.1172/JCI24898. View

Quittner A, Modi A, Wainwright C, Otto K, Kirihara J, Montgomery A . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest. 2009; 135(6):1610-1618. PMC: 2821291. DOI: 10.1378/chest.08-1190. View

Tiddens H, Donaldson S, Rosenfeld M, Pare P . Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?. Pediatr Pulmonol. 2010; 45(2):107-17. DOI: 10.1002/ppul.21154. View

Sanders D, Bittner R, Rosenfeld M, Redding G, Goss C . Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol. 2010; 46(4):393-400. DOI: 10.1002/ppul.21374. View

Ramsey B, Davies J, McElvaney N, Tullis E, Bell S, Drevinek P . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. PMC: 3230303. DOI: 10.1056/NEJMoa1105185. View

Flume P, Liou T, Borowitz D, Li H, Yen K, Ordonez C . Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012; 142(3):718-724. PMC: 3435140. DOI: 10.1378/chest.11-2672. View

Ferec C, Cutting G . Assessing the Disease-Liability of Mutations in CFTR. Cold Spring Harb Perspect Med. 2012; 2(12):a009480. PMC: 3543074. DOI: 10.1101/cshperspect.a009480. View

Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M . Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014; 18(18):1-106. PMC: 4780965. DOI: 10.3310/hta18180. View

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

10.

Boyle M, Bell S, Konstan M, McColley S, Rowe S, Rietschel E . A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014; 2(7):527-38. DOI: 10.1016/S2213-2600(14)70132-8. View

11.

De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G . Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014; 13(6):674-80. DOI: 10.1016/j.jcf.2014.09.005. View

12.

Kerem B, Rommens J, Buchanan J, Markiewicz D, Cox T, Chakravarti A . Identification of the cystic fibrosis gene: genetic analysis. Science. 1989; 245(4922):1073-80. DOI: 10.1126/science.2570460. View

13.

Wainwright C, Elborn J, Ramsey B, Marigowda G, Huang X, Cipolli M . Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015; 373(3):220-31. PMC: 4764353. DOI: 10.1056/NEJMoa1409547. View

14.

Moss R, Flume P, Elborn J, Cooke J, Rowe S, McColley S . Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015; 3(7):524-33. PMC: 4641035. DOI: 10.1016/S2213-2600(15)00201-5. View

15.

Alton E, Armstrong D, Ashby D, Bayfield K, Bilton D, Bloomfield E . Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015; 3(9):684-691. PMC: 4673100. DOI: 10.1016/S2213-2600(15)00245-3. View

16.

Davies J, Cunningham S, Harris W, Lapey A, Regelmann W, Sawicki G . Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016; 4(2):107-15. PMC: 6734927. DOI: 10.1016/S2213-2600(15)00545-7. View

17.

McColley S . A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opin Drug Saf. 2016; 15(5):709-15. DOI: 10.1517/14740338.2016.1165666. View

18.

Elborn J, Ramsey B, Boyle M, Konstan M, Huang X, Marigowda G . Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med. 2016; 4(8):617-626. PMC: 6612264. DOI: 10.1016/S2213-2600(16)30121-7. View

19.

Schneider E, Azad M, Han M, Zhou Q, Wang J, Huang J . An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. ACS Infect Dis. 2016; 2(7):478-88. PMC: 5300747. DOI: 10.1021/acsinfecdis.6b00035. View

20.

Rommens J, Iannuzzi M, Kerem B, Drumm M, Melmer G, Dean M . Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245(4922):1059-65. DOI: 10.1126/science.2772657. View